VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation

Our objective was to assess the effects of VKORC1 and CYP2C9 genotypes on severe overanticoagulation and time to achieve stability and their contributions to dose requirement during the initial phase of acenocoumarol treatment.

[1]  H. Thijssen,et al.  Acenocoumarol Pharmacokinetics in Relation to Cytochrome P450 2C9 Genotype , 2003, Clinical pharmacology and therapeutics.

[2]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[3]  D. Mcglasson.  Oral Anticoagulants , 2004, American Society for Clinical Laboratory Science.

[4]  A. Prochazka,et al.  The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. , 2005, Journal of general internal medicine.

[5]  C. Meisel,et al.  Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. , 2004, Pharmacogenetics.

[6]  A. Hofman,et al.  The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. , 2004, Pharmacogenetics.

[7]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[8]  M. Rieder,et al.  Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population , 2005, Pharmacogenetics and genomics.

[9]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[10]  T. Schalekamp,et al.  Acenocoumarol Stabilization is Delayed in CYP2C9*3 Carriers , 2004, Clinical pharmacology and therapeutics.

[11]  M. Loriot,et al.  Genetic and environmental risk factors for oral anticoagulant overdose , 2003, European Journal of Clinical Pharmacology.

[12]  J. Vandenbroucke,et al.  Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants , 1996, Thrombosis and Haemostasis.

[13]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[14]  A. Daly,et al.  Pharmacogenetics of oral anticoagulants. , 2003, Pharmacogenetics.

[15]  M. Kochen,et al.  Determination of bleeding risk using genetic markers in patients taking phenprocoumon , 2003, European Journal of Clinical Pharmacology.

[16]  H. Thijssen,et al.  The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. , 2000, Pharmacogenetics.

[17]  A. Hofman,et al.  Overanticoagulation Associated with Combined Use of Antibacterial Drugs and Acenocoumarol or Phenprocoumon Anticoagulants , 2002, Thrombosis and Haemostasis.

[18]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[19]  J. Rojas,et al.  Pharmacogenetics of oral anticoagulants , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[20]  D. Singer,et al.  Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. , 2000, Archives of internal medicine.

[21]  P. Reitsma,et al.  A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk , 2005, PLoS medicine.

[22]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[23]  M. Caldwell,et al.  Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. , 2004, Pharmacogenetics.

[24]  A. Mrhar,et al.  Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.

[25]  J. Pijoan,et al.  Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. , 2002, Haematologica.

[26]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000 .

[27]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[28]  A. Hofman,et al.  Allelic Variants of Cytochrome P450 2C9 Modify the Interaction Between Nonsteroidal Anti‐inflammatory Drugs and Coumarin Anticoagulants , 2005, Clinical pharmacology and therapeutics.

[29]  E. Spina,et al.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.

[30]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[31]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.

[32]  D. Tregouet,et al.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.

[33]  G. Marchetti,et al.  Risks factors for highly unstable response to oral anticoagulation: a case‐control study , 2005, British journal of haematology.

[34]  H. Echizen,et al.  CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences , 2004, Clinical pharmacology and therapeutics.

[35]  M. Margaglione,et al.  Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.

[36]  B. Stricker,et al.  Characteristics of Anticoagulant Therapy and Comorbidity Related to Overanticoagulation , 2001, Thrombosis and Haemostasis.

[37]  H. Thijssen,et al.  Altered pharmacokinetics of R‐ and S‐acenocoumarol in a subject heterozygous for CYP2C9*3 , 2001, Clinical pharmacology and therapeutics.

[38]  T. Wienker,et al.  VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.

[39]  S. McGrath,et al.  Cytochrome P450 polymorphisms are associated with reduced warfarin dose. , 2000, Surgery.

[40]  A. Hofman,et al.  The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants , 2004, British journal of haematology.

[41]  T. Schalekamp,et al.  Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status , 2004, Clinical pharmacology and therapeutics.

[42]  T. Baglin,et al.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. , 2000, Blood.

[43]  F. Kamali,et al.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.

[44]  A. Khvorova,et al.  Identification of the gene for vitamin K epoxide reductase , 2004, Nature.

[45]  M. Loriot,et al.  A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistance , 2005, Journal of thrombosis and haemostasis : JTH.